In order to ensure the highest quality of our services, we use small files called cookies. When using our website, the cookie files are downloaded onto your device. You can change the settings of your browser at any time. In addition, your use of our website is tantamount to your consent to the processing of your personal data provided by electronic means.

The National Centre for Research and Development

Back
logo of the Inteligenty Development Program PL the European Union logo

Production of allogeneic mesenchymal stem cells isolated from adipose tissue in accordance with the requirements of Good Manufacturing Practice

baner_successes

square with tentacles  Project title

Production of allogeneic mesenchymal stem cells isolated from adipose tissue in accordance with the requirements of Good Manufacturing Practice - active substance for the investigational advanced therapy veterinary medicinal product intended for clinical trials in the treatment of degenerative joint changes and dysplasia in dogs

outline of the upper man silhouette  Name of Beneficiary/Beneficiaries

Bioceltix S.A.

briefcase icon  Name of programme

Smart Growth Operational Program 2014-2020

newspaper icon  Competition

Action 1.1.1. Industrial research and development work

two heaps of coins icon  Project value

PLN 4 520 762,90

hand icon with two circles above it  Funding value

PLN 2 712 457,74

clock icon  Project delivery period

03.2017 – 08.2021

Get to know our team

Łukasz Bzdzion – president of the management board

Dr. Eng. Paweł Wielgus – member of the management board

See the effect of our work

Video

What problem does our project solve?

We are working on medicines for dogs and horses, and in the future also for cats. We use our proprietary ALLO-BCLX technology. We are developing biological drugs that, in addition to their symptomatic action, will also have a causal effect by influencing the inflammatory environment and activating natural mechanisms for the reconstruction of diseased tissues. Thanks to this, future Bioceltix drugs will cause fewer side effects and have a long-lasting effect after just one administration.

As part of the NCBR program, we received funding for a project related to our drug candidate BCX-CM-J, intended for the treatment of joint inflammation in dogs. NCBR supported the project from the moment of preclinical research. What distinguishes this project - also on a global scale - is that for the needs of product development, we have created our own factory in accordance with the GMP pharmaceutical standard. This allowed us to become one of the few centers of this type in the world. To this day, we are the only biotechnology company with the GMP status for working with biological drugs for animals in Poland.

Who will benefit from the project results?

The direct beneficiaries of our project will be dogs who will be able to receive more effective treatment. Due to the relationship between animals and their guardians, it can be said that the results of our project will also benefit people - dog guardians, who will be able to take better care of their animals' health. In turn, considering the fact that we are setting new standards in veterinary medicine, we can assume that the entire industry will benefit from the results of our project.

{"register":{"columns":[]}}